GlassScriptPhysician profile
Daniel L Schwartz
NPI 1811334972
$11,882.68
in general payments reported to CMS, 2019-2025
29 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $1,243 · 2021: $499 · 2022: $777 · 2023: $2,041 · 2024: $4,821 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,280 · Consulting Fee: $2,500 · Education: $9.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,280.13 |
| Consulting Fee | $2,500.00 |
| Education | $9.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $3,409.14 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Vision LLC | $1,329.51 | 2019-2025 | Wavelight Refractive Suite, Hydrus Microstent, Argos |
| Ge Healthcare | $939.27 | 2020 | |
| Glaukos Corporation | $920.73 | 2021-2025 | Kxl System (Not Refurbished), Idosetr, Istent Trabecular Micro-Bypass Stent System |
| Abbvie INC. | $721.62 | 2022-2025 | Lumigan |
| Oyster Point Pharma, INC. | $702.45 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $467.61 | 2020-2025 | Cequa |
| Dompe US, INC. | $427.03 | 2020-2025 | Oxervate |
| Biotissue Holdings INC. | $403.20 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $321.60 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $284.18 | 2019-2021 | |
| Allergan, INC. | $270.52 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $242.49 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Tarsus Pharmaceuticals, INC. | $218.21 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $202.96 | 2022-2023 | Tepezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $182.76 | 2021-2023 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $142.10 | 2021 | |
| Amgen INC. | $141.70 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $106.25 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $99.93 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $99.58 | 2023 | Tecnis Iol |
| Apellis Pharmaceuticals, INC. | $53.82 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $42.82 | 2020-2021 | |
| Optos, INC. | $41.00 | 2021 | |
| New World Medical,INC. | $30.38 | 2022 | |
| Merz North America, INC. | $25.81 | 2022 | |
| Thea Pharma INC. | $24.49 | 2023 | Iyuzeh |
| Omeros Corporation | $17.41 | 2020 | |
| Lkc Technologies, INC. | $14.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.